Anika Großhennig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anika Großhennig has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
- Armin Koch
Institute for Biostatistics, Hannover Medical School, Hannover, Germany
7 shared publications Armin Koch
Institute for Biostatistics, Hannover Medical School , Hannover
6 shared publicationsHeiko von der Leyen
Orgenesis, Inc, Germantown, MD, USA
4 shared publications- Johann Bauersachs
Department of Cardiology and Angiology, Hannover Medical School , Hannover
4 shared publications - Nele Henrike Thomas
Institute for Biostatistics, Hannover Medical School, Hannover, Germany
4 shared publications - Udo Bavendiek
Department of Cardiology and Angiology, Hannover Medical School , Hannover
4 shared publications
Latest Publications
- 29 August 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Cost-effectiveness of digitoxin in heart failure with reduced ejection fraction in the European Union and the United States
Aims: Digitoxin reduced the composite of death or worsening heart failure in DIGIT-HF, but whether these benefits translate into economic value remains unknown. We assessed its cost-effectiveness as add-on therapy for heart failure with reduced ejection fraction (HFrEF) across all 27 European Union Member States (EU-27) and the United States (US). Methods: We developed a DIGIT-HF-informed, multi-jurisdictional three-state Markov cost-utility model projecting 10-year and lifetime outcomes. Clinical risks and intention-to-treat effects were held constant; hospitalization costs, EQ-5D-5L utilities, digitoxin costs, discounting, and willingness-to-pay (WTP) thresholds varied by jurisdiction. Uncertainty was assessed using 10 000 probabilistic simulations. Results: Across the EU-27, digitoxin was cost-effective at 10 years, with incremental costs of −€338 to +€25 per patient, incremental quality-adjusted life-years (QALYs) of 0.188–0.231, and a maximum incremental cost-effectiveness ratio (ICER) of €120/QALY. Over lifetime, corresponding ranges were −€79 to +€72, 0.373–0.453 QALYs, and a maximum ICER of €174/QALY. At €50 000/QALY, cost-effectiveness probability was 92%. Digitoxin was cost-saving in 24 of 27 Member States at 10 years and 10 of 27 over lifetime. In the USA, it was cost-saving (lifetime savings US$405 per patient; 0.43 QALYs; 93.4% probability of cost-effectiveness). Conclusion: Digitoxin generated clinically meaningful health benefits at negligible incremental cost and remained cost-effective across every evaluated EU-27 healthcare system and the USA. Economic value emerged earliest within the first decade and in higher-cost hospital systems, while lifetime analysis captured larger cumulative gains in quality-adjusted survival.
- 29 August 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Cost-effectiveness of digitoxin in heart failure with reduced ejection fraction in the European Union and the United States
Aims: Digitoxin reduced the composite of death or worsening heart failure in DIGIT-HF, but whether these benefits translate into economic value remains unknown. We assessed its cost-effectiveness as add-on therapy for heart failure with reduced ejection fraction (HFrEF) across all 27 European Union Member States (EU-27) and the United States (US). Methods: We developed a DIGIT-HF-informed, multi-jurisdictional three-state Markov cost-utility model projecting 10-year and lifetime outcomes. Clinical risks and intention-to-treat effects were held constant; hospitalization costs, EQ-5D-5L utilities, digitoxin costs, discounting, and willingness-to-pay (WTP) thresholds varied by jurisdiction. Uncertainty was assessed using 10 000 probabilistic simulations. Results: Across the EU-27, digitoxin was cost-effective at 10 years, with incremental costs of −€338 to +€25 per patient, incremental quality-adjusted life-years (QALYs) of 0.188–0.231, and a maximum incremental cost-effectiveness ratio (ICER) of €120/QALY. Over lifetime, corresponding ranges were −€79 to +€72, 0.373–0.453 QALYs, and a maximum ICER of €174/QALY. At €50 000/QALY, cost-effectiveness probability was 92%. Digitoxin was cost-saving in 24 of 27 Member States at 10 years and 10 of 27 over lifetime. In the USA, it was cost-saving (lifetime savings US$405 per patient; 0.43 QALYs; 93.4% probability of cost-effectiveness). Conclusion: Digitoxin generated clinically meaningful health benefits at negligible incremental cost and remained cost-effective across every evaluated EU-27 healthcare system and the USA. Economic value emerged earliest within the first decade and in higher-cost hospital systems, while lifetime analysis captured larger cumulative gains in quality-adjusted survival.
- Open Access
- 17 August 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (9)
Immune monitoring by Torque Teno virus load in addition to virus-specific T cells after pediatric kidney transplantation
Pharmacokinetic monitoring is insufficient to estimate the intensity of immunosuppression after kidney transplantation (Tx). The randomized controlled IVIST trial demonstrated that additional steering of immunosuppressive therapy by virus-specific CD4+ T cells (Tvis) is safe and reduces exposure to immunosuppressants. The adenovirus-specific CD4+ T cells (ADV-Tvis) proved to be particularly suitable due to their stability and high prevalence. Another promising biomarker for post-Tx immunomonitoring is the Torque Teno virus (TTV) but pediatric data are very limited. This descriptive longitudinal analysis aimed to evaluate the post-Tx course of TTV load compared to Tvis levels after pediatric Tx. In the IVIST trial, 31 pediatric kidney recipients were randomized to the intervention group with Tvis-guided immunosuppression. The immunosuppressive therapy consisted of basiliximab, cyclosporine A (CsA), everolimus (Eve), and prednisolone. In 27 out of 31 intervention group patients, TTV-DNA was analysed retrospectively in frozen plasma samples from 20 visits [1–24 months (mo) after Tx]. Associations of TTV-DNA with ADV-Tvis and with immunosuppressants over the post-Tx period were evaluated using linear mixed models, adjusted for time since Tx and accounting for repeated measurements within patients. Mean TTV-DNA (n = 474) ± standard deviation was 4.4 ± 1.3 log10 copies/ml (1.4 to 9.4 log10). TTV-DNA was associated with post-Tx follow-up time. Under intensive immunosuppression immediately after Tx, TTV-DNA increased, peaking at 3 mo post-Tx (5.5 ± 1.4 log10); after reduction of immunosuppression, TTV load decreased (6 mo: 4.3 ± 1.1 log10; 16 mo: 3.9 ± 0.9 log10). Mean ADV-Tvis levels showed a minimum at 2 mo post-Tx and increased over time: from 1.5 ± 1.1 cells/µl (2 mo) to 2.0 ± 1.8 cells/µl (6 mo) and 2.4 ± 1.7 cells/µl (22 mo). TTV-DNA showed overall positive correlations with mean daily doses and trough levels of CsA and Eve. The longitudinal analysis of TTV load presented an opposite post-Tx course compared to ADV-Tvis. TTV-DNA was associated with post-Tx follow-up time and with immunosuppressants after pediatric Tx. In comparison to ADV-Tvis minimum, the mean TTV-DNA showed a late peak at 3 mo post-Tx suggesting delayed response to drug dose changes.
- 17 August 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (9)
Open AccessImmune monitoring by Torque Teno virus load in addition to virus-specific T cells after pediatric kidney transplantation
Pharmacokinetic monitoring is insufficient to estimate the intensity of immunosuppression after kidney transplantation (Tx). The randomized controlled IVIST trial demonstrated that additional steering of immunosuppressive therapy by virus-specific CD4+ T cells (Tvis) is safe and reduces exposure to immunosuppressants. The adenovirus-specific CD4+ T cells (ADV-Tvis) proved to be particularly suitable due to their stability and high prevalence. Another promising biomarker for post-Tx immunomonitoring is the Torque Teno virus (TTV) but pediatric data are very limited. This descriptive longitudinal analysis aimed to evaluate the post-Tx course of TTV load compared to Tvis levels after pediatric Tx. In the IVIST trial, 31 pediatric kidney recipients were randomized to the intervention group with Tvis-guided immunosuppression. The immunosuppressive therapy consisted of basiliximab, cyclosporine A (CsA), everolimus (Eve), and prednisolone. In 27 out of 31 intervention group patients, TTV-DNA was analysed retrospectively in frozen plasma samples from 20 visits [1–24 months (mo) after Tx]. Associations of TTV-DNA with ADV-Tvis and with immunosuppressants over the post-Tx period were evaluated using linear mixed models, adjusted for time since Tx and accounting for repeated measurements within patients. Mean TTV-DNA (n = 474) ± standard deviation was 4.4 ± 1.3 log10 copies/ml (1.4 to 9.4 log10). TTV-DNA was associated with post-Tx follow-up time. Under intensive immunosuppression immediately after Tx, TTV-DNA increased, peaking at 3 mo post-Tx (5.5 ± 1.4 log10); after reduction of immunosuppression, TTV load decreased (6 mo: 4.3 ± 1.1 log10; 16 mo: 3.9 ± 0.9 log10). Mean ADV-Tvis levels showed a minimum at 2 mo post-Tx and increased over time: from 1.5 ± 1.1 cells/µl (2 mo) to 2.0 ± 1.8 cells/µl (6 mo) and 2.4 ± 1.7 cells/µl (22 mo). TTV-DNA showed overall positive correlations with mean daily doses and trough levels of CsA and Eve. The longitudinal analysis of TTV load presented an opposite post-Tx course compared to ADV-Tvis. TTV-DNA was associated with post-Tx follow-up time and with immunosuppressants after pediatric Tx. In comparison to ADV-Tvis minimum, the mean TTV-DNA showed a late peak at 3 mo post-Tx suggesting delayed response to drug dose changes.
- Open Access
- 28 May 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (7) , e014396
DIGIT-HF: Results From the Win Ratio Analyses
- 28 May 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (7) , e014396
Open AccessDIGIT-HF: Results From the Win Ratio Analyses
- Open Access
- 10 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (38) , 5597-5601
Digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation status: the DIGIT-HF trial
- 10 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (38) , 5597-5601
Open AccessDigitoxin in heart failure with reduced ejection fraction according to atrial fibrillation status: the DIGIT-HF trial
- Open Access
- 17 February 2026
- Published by Wiley in Pharmaceutical Statistics
- Vol. 25 (2) , e70078
A Statistical Concept for Conditional Marketing Authorisation Based on the Intermediate and Final Outcomes of a Single Confirmatory Randomised Clinical Trial
Conditional marketing authorisation (CMA) is a path to early market access of new medicines addressing an unmet medical need in the European Union (EU), and similar concepts exist in other regulatory regions. For justifying a CMA, the benefit‐risk ratio has to be positive, and the applicant must be able to provide comprehensive data post‐authorisation for converting the CMA to a full marketing authorisation (MA). A recent proposal is to plan a single randomised clinical trial with interim analyses and base the decision for CMA and full MA on an intermediate and a final primary endpoint. To control the study‐wise type‐1‐error (T1E), the dual primary endpoint concept, essentially a Bonferroni‐split of the study‐wise T1E between the intermediate and final endpoints, has been proposed. We argue that the resulting statistical definition of formal study success is not in line with clinical assessment of the overall trial outcome. Consistent with the European Medicines Agency (EMA) guideline on multiplicity issues in clinical trials, the intermediate and final endpoints should be co‐primary, and we propose that each is assessed with a standard group sequential design. We illustrate our proposal using an oncology phase III trial with complete remission (CR) as the intermediate and overall survival (OS) as the final primary endpoint. Based on the example, we demonstrate that our proposal is a valid and flexible alternative with minimal to no impact on costs in terms of sample size or timing of the interim analysis intended for applying for a CMA but it improves the interpretation of the overall trial outcome.
- 17 February 2026
- Published by Wiley in Pharmaceutical Statistics
- Vol. 25 (2) , e70078
Open AccessA Statistical Concept for Conditional Marketing Authorisation Based on the Intermediate and Final Outcomes of a Single Confirmatory Randomised Clinical Trial
Conditional marketing authorisation (CMA) is a path to early market access of new medicines addressing an unmet medical need in the European Union (EU), and similar concepts exist in other regulatory regions. For justifying a CMA, the benefit‐risk ratio has to be positive, and the applicant must be able to provide comprehensive data post‐authorisation for converting the CMA to a full marketing authorisation (MA). A recent proposal is to plan a single randomised clinical trial with interim analyses and base the decision for CMA and full MA on an intermediate and a final primary endpoint. To control the study‐wise type‐1‐error (T1E), the dual primary endpoint concept, essentially a Bonferroni‐split of the study‐wise T1E between the intermediate and final endpoints, has been proposed. We argue that the resulting statistical definition of formal study success is not in line with clinical assessment of the overall trial outcome. Consistent with the European Medicines Agency (EMA) guideline on multiplicity issues in clinical trials, the intermediate and final endpoints should be co‐primary, and we propose that each is assessed with a standard group sequential design. We illustrate our proposal using an oncology phase III trial with complete remission (CR) as the intermediate and overall survival (OS) as the final primary endpoint. Based on the example, we demonstrate that our proposal is a valid and flexible alternative with minimal to no impact on costs in terms of sample size or timing of the interim analysis intended for applying for a CMA but it improves the interpretation of the overall trial outcome.
- Open Access
- 8 July 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (9) , 2750-2754
Randomization in phase II trials: No exemption based on sample size
Conducting randomized clinical trials (RCTs) is challenging. For this reason, in earlier phases of drug development and rare diseases with limited sample sizes, there is a tendency to omit control groups and to replace them with historical information for perceived feasibility arguments. This has significant implications for interpretation of trial results. We present headline results from a trial in stem cell transplantation, where fludarabine and clofarabine were investigated for induction chemotherapy in high‐risk acute myeloid leukaemia or advanced myelodysplastic syndrome. The trial was initially designed as single‐arm trial (SAT) and is discussed here from the planning and assessment perspective. Changes in the treatment setting or patient selection may lead to ‘promising results’ in SATs, which are difficult to identify and may raise unwarranted hopes which cannot be confirmed in a subsequent randomized trial. RCTs should be used to achieve a straightforward interpretation of the results, even if the sample size is small. Interpreting SATs is only straightforward in very rare instances where the underlying treatment effect is large and the outcome in each individual patient surpasses all previous clinical experience.
- 8 July 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (9) , 2750-2754
Open AccessRandomization in phase II trials: No exemption based on sample size
Conducting randomized clinical trials (RCTs) is challenging. For this reason, in earlier phases of drug development and rare diseases with limited sample sizes, there is a tendency to omit control groups and to replace them with historical information for perceived feasibility arguments. This has significant implications for interpretation of trial results. We present headline results from a trial in stem cell transplantation, where fludarabine and clofarabine were investigated for induction chemotherapy in high‐risk acute myeloid leukaemia or advanced myelodysplastic syndrome. The trial was initially designed as single‐arm trial (SAT) and is discussed here from the planning and assessment perspective. Changes in the treatment setting or patient selection may lead to ‘promising results’ in SATs, which are difficult to identify and may raise unwarranted hopes which cannot be confirmed in a subsequent randomized trial. RCTs should be used to achieve a straightforward interpretation of the results, even if the sample size is small. Interpreting SATs is only straightforward in very rare instances where the underlying treatment effect is large and the outcome in each individual patient surpasses all previous clinical experience.
- Open Access
- 3 January 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (1)
Cancer risk in carriers of TP53 germline variants grouped into different functional categories
Li-Fraumeni syndrome is a cancer predisposition syndrome caused by pathogenic TP53 germline variants; it is associated with a high lifelong cancer risk. We analyzed the German Li-Fraumeni syndrome registry, which contains data on 304 individuals. Cancer phenotypes were correlated with variants grouped according to their ability to transactivate target genes in a yeast assay using a traditional (nonfunctional, partially functional) and a novel (clusters A, B, and C) classification of variants into different groups. Partially functional and cluster B or C variants were enriched in patients who did not meet clinical testing criteria. Time to first malignancy was longer in carriers of partially functional variants (hazard ratio = 0.38, 95% CI = 0.22 to 0.66). Variants grouped within cluster B (hazard ratio = 0.45, 95% CI = 0.28 to 0.71) or C (hazard ratio = 0.34, 95% CI = 0.19 to 0.62) were associated with later cancer onset than NULL variants. These findings can be used to risk-stratify patients and inform care.
- 3 January 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (1)
Open AccessCancer risk in carriers of TP53 germline variants grouped into different functional categories
Li-Fraumeni syndrome is a cancer predisposition syndrome caused by pathogenic TP53 germline variants; it is associated with a high lifelong cancer risk. We analyzed the German Li-Fraumeni syndrome registry, which contains data on 304 individuals. Cancer phenotypes were correlated with variants grouped according to their ability to transactivate target genes in a yeast assay using a traditional (nonfunctional, partially functional) and a novel (clusters A, B, and C) classification of variants into different groups. Partially functional and cluster B or C variants were enriched in patients who did not meet clinical testing criteria. Time to first malignancy was longer in carriers of partially functional variants (hazard ratio = 0.38, 95% CI = 0.22 to 0.66). Variants grouped within cluster B (hazard ratio = 0.45, 95% CI = 0.28 to 0.71) or C (hazard ratio = 0.34, 95% CI = 0.19 to 0.62) were associated with later cancer onset than NULL variants. These findings can be used to risk-stratify patients and inform care.
- 1 October 2024
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 9 (5) , 1349-1359
The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial
Background: The multicenter, randomized, double-blind, parallel-group, phase IIIb CANNA-TICS (CANNAbinoids in the treatment of TICS) trial showed clear trends for improvement of tics, depression, and quality of life with nabiximols versus placebo in adult patients with Gilles de la Tourette syndrome and other chronic tic disorders. Although in general nabiximols was well tolerated, it is unclear whether treatment using this cannabis extract influences driving skills in patients with chronic tic disorders. Methods: Here we report results of the “Fitness to Drive” substudy of the CANNA-TICS trial. The key endpoint was fitness to drive as a binary criterion with a computerized assessment at baseline and after 9 weeks of stable treatment (week 13) with nabiximols or placebo. A patient was considered unfit to drive according to the German Federal Highway Research Institute guidelines. Results: In the substudy, a total of 64 patients (76.6% men, mean±standard deviation of age: 36.8±13.9) were recruited at two study sites. The number of patients who were fit to drive increased from 24 (55.8%) at baseline to 28 (71.8%) at week 13 among 43 patients treated with nabiximols, and decreased from 14 (66.7%) to 10 (52.6%) among 21 patients who received placebo. The risk difference (nabiximols – placebo) was 0.17 (95% confidence interval=−0.08 to 0.43) in favor of nabiximols. Specifically, only 2 of 24 (8.3%) patients in the nabiximols, but 4 of 14 (28.6%) patients in the placebo group changed for the worse from fit (at baseline) to unfit (at week 13) to drive, whereas 8 of 19 (42.1%) patients in the nabiximols, and only 2 of 7 (28.6%) patients in the placebo group improved from unfit to fit. Conclusion: Treatment with nabiximols does not impair skills relevant to driving in those patients with tic disorders who were fit to drive at baseline and even improved fitness to drive in a subset of patients who were unfit to drive before start of treatment. EudraCT number: : 2016-000564-42
- 1 October 2024
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 9 (5) , 1349-1359
The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial
Background: The multicenter, randomized, double-blind, parallel-group, phase IIIb CANNA-TICS (CANNAbinoids in the treatment of TICS) trial showed clear trends for improvement of tics, depression, and quality of life with nabiximols versus placebo in adult patients with Gilles de la Tourette syndrome and other chronic tic disorders. Although in general nabiximols was well tolerated, it is unclear whether treatment using this cannabis extract influences driving skills in patients with chronic tic disorders. Methods: Here we report results of the “Fitness to Drive” substudy of the CANNA-TICS trial. The key endpoint was fitness to drive as a binary criterion with a computerized assessment at baseline and after 9 weeks of stable treatment (week 13) with nabiximols or placebo. A patient was considered unfit to drive according to the German Federal Highway Research Institute guidelines. Results: In the substudy, a total of 64 patients (76.6% men, mean±standard deviation of age: 36.8±13.9) were recruited at two study sites. The number of patients who were fit to drive increased from 24 (55.8%) at baseline to 28 (71.8%) at week 13 among 43 patients treated with nabiximols, and decreased from 14 (66.7%) to 10 (52.6%) among 21 patients who received placebo. The risk difference (nabiximols – placebo) was 0.17 (95% confidence interval=−0.08 to 0.43) in favor of nabiximols. Specifically, only 2 of 24 (8.3%) patients in the nabiximols, but 4 of 14 (28.6%) patients in the placebo group changed for the worse from fit (at baseline) to unfit (at week 13) to drive, whereas 8 of 19 (42.1%) patients in the nabiximols, and only 2 of 7 (28.6%) patients in the placebo group improved from unfit to fit. Conclusion: Treatment with nabiximols does not impair skills relevant to driving in those patients with tic disorders who were fit to drive at baseline and even improved fitness to drive in a subset of patients who were unfit to drive before start of treatment. EudraCT number: : 2016-000564-42
- 20 September 2024
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 121 (19) , 634-638
Recognizing statistical problems in reports of clinical trials: a readers’ aid
In clinical research, both experimental and observational studies play a decisive role in the development of new drugs and treatment methods. Methodological standards have been established for the conduct of studies and the creation of study...
- 20 September 2024
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 121 (19) , 634-638
Recognizing statistical problems in reports of clinical trials: a readers’ aid
In clinical research, both experimental and observational studies play a decisive role in the development of new drugs and treatment methods. Methodological standards have been established for the conduct of studies and the creation of study...